THRIVE-SVR

THRIVE-SVR: StraTified Medicine Research to Support Hepatocellular Carcinoma ScReening DecIsions for HCV Cirrhosis PatiEnts after Sustained Viral Response

(2020-2023)

The THRIVE-SVR study will develop new prediction tools to estimate the benefit of liver cancer surveillance for patients with cirrhosis and a hepatitis C cure. The goal is to help clinicians identify those patients who stand to gain the most from surveillance (and vice versa, those who are likely to benefit minimally or not at all). There are so many why research in this area is important. One key issue is that there has been a huge increase in the number of patients with liver cirrhosis who have achieved a hepatitis C “cure” – and we don’t really understand right now which patients need to be screened for hepatocellular carcinoma and which (if any) do not. Also, liver cancer screening is currently performed in a very ad-hoc way in many clinics. Thus, the prediction models we develop will help facilitate a more systematic approach to screening, ensuring screening equity for all patients. The modelling framework we develop could also be adapted to liver cancer screening for other forms of liver disease - e.g. alcohol liver disease where the same issues apply.

Project team

Hamish Innes (Principal investigator, Glasgow Caledonian University), Neil Guha, Will Irving (University of Nottingham); Eleanor Banes (University Oxford); British Liver Trust; Philip Johnson (University of Liverpool); Sharon Hutchinson (GCU); Scott McDonald (GCU); Naveed Janjua (University of British Columbia)

Contact: hamish.innes@gcu.ac.uk

Funded by the Medical Research Foundation